About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Boston | 13,548 Studies Near You | Clareo Health

Clinical Trials LocationsBoston

Clinical Trials in Boston

Discover 13,548 clinical trials near Boston, Massachusetts. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 6841-6860 of 13,548 trials

COMPLETEDPhase 1< 1 mile

A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

NCT00999401

A study of sequential administration of oral sapacitabine and oral Seliciclib in patients with advanced solid tumors.

Advanced Solid Tumors

Cyclacel Pharmaceuticals, Inc.103 participantsStarted Apr 2009

Boston, Massachusetts, United States • Boston, Massachusetts, United States

TERMINATEDPhase 2< 1 mile

Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

NCT00372073

A phase 2 study to evaluate efficacy of oral seliciclib in treating non-small cell lung cancer (NSCLC).

Non-small Cell Lung Cancer

Cyclacel Pharmaceuticals, Inc.187 participantsStarted Aug 2006

Tucson, Arizona, United States • Fountain Valley, California, United States • New Port Richey, Florida, United States +17 more locations

Find Trials by Condition in Boston

Breast Cancerin Boston Lung Cancerin Boston Prostate Cancerin Boston Colorectal Cancerin Boston Melanomain Boston Leukemiain Boston Lymphomain Boston Pancreatic Cancerin Boston Ovarian Cancerin Boston Brain Cancerin Boston Diabetesin Boston

Data from ClinicalTrials.govTerms

COMPLETEDNA< 1 mile

Virtual Reality Alternative to Pharmacological Sedation During Colonoscopy

NCT04349150

Colonoscopy patients will be fitted with a virtual reality head-mounted display, and virtual experiences will be initiated prior to colonoscope insertion. Colonoscopy will be initiated without standard sedatives and narcotics. The colonoscopy will proceed with the subject using virtual reality distraction instead of pharmacological sedation for as long as s/he would like. Standard sedatives and narcotics will be administered upon participant request at any time during the procedure. Questionnaires will be administered to the subject and the endoscopist after each procedure to assess the acceptability of use of virtual reality in the colonoscopy setting.

Massachusetts General Hospital31 participantsStarted May 2019

Boston, Massachusetts, United States

WITHDRAWNPhase 4< 1 mile

Assessment of Intravenous Rate Control Response in Atrial Fibrillation Trial (AIRCRAFT)

NCT04234477

The Assessment of Intravenous Rate Control Response in Atrial Fibrillation Trial Pilot Study (AIRCRAFT Pilot) is a prospective, unblinded, pragmatic, cluster-level allocation trial. AIRCRAFT compares two medication classes commonly used for rate control in patients in atrial fibrillation (AF) with rapid ventricular rate (RVR). The purpose of this pilot study is to evaluate the feasibility and approach to conducting a trial that compares the use of IV beta blockers and IV calcium channel blockers for patients in AF with RVR in the medical intensive care unit (MICU). AF with RVR is considered when the following parameters are met: (1) Cardiac rhythm consistent with AF (2) Heart rate \> 110 bpm. AF with RVR recurrence after conversion to sinus rhythm or prior rate control will count as a new episode of AF with RVR. Rate control agents will be pseudo-randomized to each of the three different MICU teams (beta-blocker, calcium channel blocker and physician preference). Patients are admitted to the three MICU teams on a rotating basis which will allow for pseudo-randomization, the effects of which will be equal between the three teams. Patients will be enrolled in the study if they develop AF with RVR and will be followed until discharge from the MICU. This study aims to assess the adherence and fidelity to treatment assignments in the current novel pilot study protocol which will help inform the feasibility of a larger-scale efficacy trial between IV beta blockers and IV calcium channel blockers for initial management of AF with RVR. Assessment of adherence and fidelity to treatment assignments in management of AF with RVR in the MICU will help inform power calculations and the percent of patients in each study group that received the assigned class of medication will help inform feasibility. Additional aims include assessment of time from medication administration to rate control or sinus conversion as well as identifying optimal means of data extraction (manual vs automated), and incidence of adverse events including hypotension and bradycardia.

Atrial Fibrillation

Boston UniversityStarted Dec 2021

Boston, Massachusetts, United States

COMPLETEDNA< 1 mile

Randomized Endo-Vein Graft Prospective

NCT01850082

Coronary artery bypass grafting (CABG) is the most common major surgical procedure in the United States with over 300,000 cases performed each year. To restore blood flow to the heart, vascular conduits from another part of the body are procured to create a bypass around critically blocked coronary arteries. The left internal thoracic artery is the conduit of choice for CABG due to its superior long-term patency. However, almost all patients referred for CABG require additional grafts to provide complete revascularization. This necessitates the harvest of other vessels, most commonly the saphenous vein which is used almost ubiquitously in contemporary CABG with an average of two vein grafts per CABG procedure. In the last 10 years, Endoscopic Vein Harvesting (EVH) has been recommended as the preferred method over the traditional open harvesting technique (OVH) because it provides a minimally invasive approach. However, more recent investigations indicate potential for reduced long-term bypass graft patency and worse clinical outcomes with EVH. The long term impact of EVH on clinical outcomes has never been investigated on a large scale using a definitive, adequately powered, prospective Randomized Controlled Trial (RCT) with long-term follow-up.

Coronary Artery Bypass Grafting

VA Office of Research and Development1,150 participantsStarted Sep 2013

Tucson, Arizona, United States • San Francisco, California, United States • Gainesville, Florida, United States +13 more locations

COMPLETEDPhase 2< 1 mile

Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

NCT03283371

The primary efficacy objective of the study is to determine if adjunctive therapy of natalizumab 300 mg intravenous (IV) every 4 weeks reduces the frequency of seizures in adult participants with drug-resistant focal epilepsy. The secondary efficacy objective is to assess the effects of natalizumab versus placebo in drug-resistant focal epilepsy on additional measures of seizure frequency.

Epilepsy, Focal Seizures, Partial Seizures

Biogen67 participantsStarted Mar 2018

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +28 more locations

COMPLETED< 1 mile

Reducing the Duration of Untreated Psychosis in the United States

NCT03369730

The goal of this project is to investigate whether a systematic screening approach for individuals with first episode psychosis (FEP) can substantially reduce Duration of Untreated Psychosis (DUP). The study team will evaluate the feasibility of screening a consecutive help-seeking population entering mental health services in order to facilitate early identification of FEP cases, rapid referral to specialty care and engagement in treatment.

First Episode Psychosis (FEP)At Risk Mental State (ARMS)

Icahn School of Medicine at Mount Sinai94 participantsStarted Feb 2018

Boston, Massachusetts, United States • New York, New York, United States • New York, New York, United States

COMPLETEDNA2.6 miles

The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign

NCT04644328

Facebook ads with physician-delivered videos were shown before the Thanksgiving and Christmas holidays and focused on staying safe during the COVID pandemic by limiting travel and mask-wearing.

National Bureau of Economic Research, Inc.820 participantsStarted Nov 2020

Cambridge, Massachusetts, United States

TERMINATEDPhase 36.6 miles

Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

NCT00983437

The primary objective of this study is to evaluate the safety and tolerability of long-term (12 months) armodafinil treatment in patients with excessive sleepiness associated with mild or moderate closed traumatic brain injury (TBI).

Traumatic Brain Injury

Cephalon, Inc.49 participantsStarted Aug 2009

Birmingham, Alabama, United States • Tucson, Arizona, United States • Hot Springs, Arkansas, United States +58 more locations

COMPLETEDPhase 310 miles

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

NCT03436199

This study assessed the efficacy and safety of ADS-5102 (at daily doses of 137 mg or 274 mg) compared with placebo in MS patients with walking impairment.

Walking ImpairmentMultiple Sclerosis

Adamas Pharmaceuticals, Inc.558 participantsStarted Mar 2018

Cullman, Alabama, United States • Phoenix, Arizona, United States • Scottsdale, Arizona, United States +81 more locations

COMPLETEDPhase 316 miles

Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris

NCT03915860

Participant Reported Outcomes with use of Trifarotene 50 μg/g Cream in participants with Moderate Facial and Truncal Acne Vulgaris

Galderma R&D47 participantsStarted Mar 2019

Fort Smith, Arkansas, United States • Beverly, Massachusetts, United States • Portsmouth, New Hampshire, United States +6 more locations

COMPLETEDPhase 221 miles

Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)

NCT03452397

The objective of this study is to evaluate the safety and effectiveness of OC-02 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease.

Dry Eye Disease

Oyster Point Pharma, Inc.165 participantsStarted Feb 2018

Louisville, Kentucky, United States • Andover, Massachusetts, United States • Nashville, Tennessee, United States

COMPLETEDPhase 141 miles

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

NCT01772004

This is a Phase 1, open-label, dose-escalation trial of avelumab \[antibody targeting programmed death ligand 1 (anti PD-L1)\] with consecutive parallel group expansion in participants with selected tumor indications. New recruitment is open for all active cohorts. Active cohorts: Escalation revised dosing regimen cohort. Closed cohorts: Non-small cell lung cancer (NSCLC, first line), NSCLC (post-platinum), metastatic breast cancer (MBC), colorectal cancer (CRC), urothelial carcinoma (secondary), mesothelioma, gastric/GEJ cancer (first line switch maintenance and second line), and ovarian cancer (secondary and platinum refractory + liposomal doxorubicin), renal cell carcinoma (second line) melanoma and head, neck squamous cell carcinoma (HNSCC), castrate-resistant prostate cancer (CRPC), adrenocortical carcinoma (ACC) urothelial carcinoma (efficacy), gastric/gastroesophageal junction (GEJ) cancer (third line), renal cell carcinoma (RCC, first line) and escalation phase .

EMD Serono Research & Development Institute, Inc.1,756 participantsStarted Jan 2013

Goodyear, Arizona, United States • Scottsdale, Arizona, United States • Scottsdale, Arizona, United States +71 more locations

COMPLETEDPhase 3121 miles

A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

NCT02631070

The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in participants with anemia due to the Revised International Prognostic Scoring System (IPSS-R) very low, low, or intermediate MDS with ring sideroblasts who require red blood cell (RBC) transfusions.

Myelodysplastic Syndromes

Celgene229 participantsStarted Feb 2016

Stanford, California, United States • New Haven, Connecticut, United States • Tampa, Florida, United States +71 more locations

COMPLETEDPhase 2190 miles

Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy

NCT03819114

The purpose of this pharmacokinetic (PK) study was to evaluate if a double dose (3 mg) of levonorgestrel (LNG) overcomes known drug-drug interactions (DDIs) with efavirenz (EFV)-based antiretroviral therapy (ART) or rifampicin (RIF)-containing tuberculosis (TB) therapy. The safety of double-dose (3.0 mg) LNG versus standard-dose (1.5 mg) was also compared.

HIV InfectionsTuberculosis

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections122 participantsStarted May 2019

Chicago, Illinois, United States • Chicago, Illinois, United States • New York, New York, United States +15 more locations

TERMINATEDPhase 2391 miles

Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.

NCT03269695

The purpose of this study is to determine if PF-06687234 is effective and safe as add-on therapy to infliximab in subjects with active ulcerative colitis who are not in remission.

Ulcerative Colitis

Pfizer20 participantsStarted Dec 2017

Dothan, Alabama, United States • Dothan, Alabama, United States • Atlanta, Georgia, United States +31 more locations

COMPLETEDNA431 miles

Comic Intervention for Sexual Violence Prevention and Post-rape Care

NCT04656522

In humanitarian settings, sexual and gender-based violence disproportionately impacts women and children. However, there continues to be a lack of evidence regarding both sexual violence prevention and post-rape care interventions in low- and middle-income humanitarian contexts, with even less evidence supporting adolescents and youth in these settings. Participatory comics offer a youth-friendly, low-cost, scalable approach for preventing sexual violence and training clinicians in post-rape care in humanitarian settings. This study aims to develop, implement, and evaluate the effectiveness of a comic intervention on preventing sexual violence and improving post-rape care with youth aged 16-24 and health care providers in the Bidi Bidi refugee settlement.

Knowledge, Attitudes, PracticePost-exposure Prophylaxis

University of Toronto100 participantsStarted Nov 2020

Toronto, Ontario, Canada • Arua, Uganda

TERMINATEDPhase 1/2576 miles

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

NCT04548791

The purpose of the trial is to evaluate the PK, bioavailability, PD, efficacy and safety of MarzAA for on demand treatment and control of bleeding episodes in adult subjects with inherited bleeding disorders.

Factor VII DeficiencyGlanzmann ThrombastheniaHemophilia A With Inhibitor

Catalyst Biosciences19 participantsStarted May 2021

Sacramento, California, United States • San Francisco, California, United States • Aurora, Colorado, United States +17 more locations

COMPLETEDPhase 2642 miles

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

NCT02639910

This is a two-cohort, multicenter, open-label study of tafasitamab (MOR208) combined with idelalisib or venetoclax in adult patients with R/R CLL or R/R SLL pretreated with a BTK inhibitor (e.g., ibrutinib) as single agent or as part of combination therapy. Patients completing the study treatment are invited to participate in an optional biomarker sub-study.

Leukemia, Lymphocytic, Chronic, B-CellChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

MorphoSys AG24 participantsStarted Nov 2016

Jacksonville, Florida, United States • Rochester, Minnesota, United States • Columbus, Ohio, United States +14 more locations

TERMINATEDPhase 1/2769 miles

A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)

NCT04498247

The primary objective of this early Phase 1/2 study is to identify the V591 dose that achieves the target immune response in humans based on preclinical or early clinical data.

Coronavirus Disease (COVID-19)

Merck Sharp & Dohme LLC263 participantsStarted Aug 2020

Hollywood, Florida, United States • Wichita, Kansas, United States • Lexington, Kentucky, United States +6 more locations

PreviousPage 343 of 678Next

Heart Diseasein Boston